TrialJournal of clinical oncology : official journal of the American Society of Clinical Oncology2021

Five-Year Outcomes With Pembrolizumab Versus Chemotherapy for Metastatic Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50.

Martin Reck et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.